Cargando…

PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells

The protein phosphatase 2A (PP2A) inhibitor, LB100, has been shown in pre-clinical studies to be an effective chemo- and radio-sensitizer for treatment of various cancers. We investigated effects associated with LB100 treatment alone and in combination with cisplatin for medulloblastoma (MB) in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Winson S., Feldman, Michael J., Maric, Dragan, Amable, Lauren, Hall, Matthew D., Feldman, Gerald M., Ray-Chaudhury, Abhik, Lizak, Martin J., Vera, Juan-Carlos, Robison, R. Aaron, Zhuang, Zhengping, Heiss, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914297/ https://www.ncbi.nlm.nih.gov/pubmed/26799670 http://dx.doi.org/10.18632/oncotarget.6970

Ejemplares similares

Characterization of the blood brain barrier in pediatric central nervous system neoplasms
por: Hong, Christopher S., et al.
Publicado: (2016)

Review of PP2A Tumor Biology and Antitumor Effects of PP2A Inhibitor LB100 in the Nervous System
por: Bryant, Jean-Paul, et al.
Publicado: (2021)

Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target
por: Sizdahkhani, Saman, et al.
Publicado: (2017)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma
por: Fang, Francia Y., et al.
Publicado: (2022)

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma
por: Cui, Jing, et al.
Publicado: (2020)

Cisplatin is retained in the cochlea indefinitely following chemotherapy
por: Breglio, Andrew M., et al.
Publicado: (2017)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
por: Shi, Zhen-duo, et al.
Publicado: (2022)

Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug
por: AMABLE, LAUREN, et al.
Publicado: (2014)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
por: Schmidtova, Silvia, et al.
Publicado: (2019)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance
por: Jiang, Xiaohan, et al.
Publicado: (2023)

Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome
por: Welch, Thomas R., et al.
Publicado: (2017)

Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats
por: Huo, Tianyao, et al.
Publicado: (2012)

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
por: Gomez-Roman, Natividad, et al.
Publicado: (2015)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
por: Hama, Taketsugu, et al.
Publicado: (2021)

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
por: Rajendran, Ganeshkumar, et al.
Publicado: (2021)

Health Benefits of Modificated Multiplatinum Derivatives as Strategies for Overcoming the Cisplatin Resistance
por: Ivanova, Stefka Achkova, et al.
Publicado: (2023)

Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma
por: Yang, So Mi, et al.
Publicado: (2023)

SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma
por: Brown, Austin L, et al.
Publicado: (2015)

MBRS-13. MiR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC MEDULLOBLASTOMA BY REGULATING FERROPTOSIS
por: Kanchan, Ranjana K, et al.
Publicado: (2020)

MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
por: Kanchan, Ranjana, et al.
Publicado: (2022)

Overcoming multiple drug resistance mechanisms in medulloblastoma
por: Othman, Ramadhan T, et al.
Publicado: (2014)

Loss of Quiescence in von Hippel-Lindau Hemangioblastomas is Associated with Erythropoietin Signaling
por: Feldman, Michael J., et al.
Publicado: (2016)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

BIOL-06. MIR-1253 POTENTIATES CISPLATIN RESPONSE IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA BY REGULATING FERROPTOSIS
por: Kanchan, Ranjana, et al.
Publicado: (2021)

Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
por: García-Cano, Jesús, et al.
Publicado: (2015)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
por: Zhao, Maoyuan, et al.
Publicado: (2020)

Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines
por: Al Balushi, Najwa, et al.
Publicado: (2022)

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
por: Hu, Chao, et al.
Publicado: (2017)

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
por: Wang, Yonggang, et al.
Publicado: (2018)

Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
por: Song, Donghui, et al.
Publicado: (2019)

The Vitamin D Receptor–BIM Axis Overcomes Cisplatin Resistance in Head and Neck Cancer
por: Khamis, Aya, et al.
Publicado: (2022)

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers
por: Rades, Dirk, et al.
Publicado: (2016)

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
por: Hu, Chao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eg3h661l2pbutuearbq6k287j0